The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

Dermitzakis, Emmanouil V.; Kimiskidis, Vasilios Κ.; Lazaridis, George; Alexopoulou, Zoi; Timotheadou, Eleni; Παπανικολάου, Αλέξανδρος; Romanidou, Ourania; Georgiadis, George S.; Kalogeras, Konstantine T.; Tsiptsios, Iakovos; Tarlatzis, Basil C.; Fountzilas, George

doi:10.1186/s12883-016-0710-4

Cited by 23 publications

(16 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an example, platinum‐based compounds have been rarely associated with acute inflammatory demyelinating polyradiculoneuritis in patients with solid tumor, which appears to respond well to standard immunotherapy. Additionally, it is important to be aware that treatment with more than one neurotoxic agent may increase the likelihood of peripheral neuropathy, which may be associated with involvement of the autonomic system (especially parasympathetic heart innervation) …”

Section: Clinical Aspects Of Pipnmentioning

confidence: 99%

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

Staff

Cavaletti

Islam

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Platinum-induced peripheral neurotoxicity (PIPN) is a common side effect of platinum-based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin being more neurotoxic. PIPN includes acute neurotoxicity restricted to oxaliplatin, and chronic non-length-dependent sensory neuronopathy with positive and negative sensory symptoms and neuropathic pain in both upper and lower limbs.Chronic sensory axonal neuropathy manifesting as stocking-and-glove distribution is also frequent. Worsening of neuropathic symptoms after completing the last chemotherapy course may occur. Motor and autonomic involvement is uncommon. Ototoxicity is frequent in children and more commonly to cisplatin. Platinum-based compounds result in more prolonged neuropathic symptoms in comparison to other chemotherapy agents. Patient reported outcomes questionnaires, clinical evaluation and instrumental tools offer complementary information in PIPN. Electrodiagnostic features include diffusely reduced/abolished sensory action potentials, in keeping with a sensory neuronopathy. PIPN is dependent on cumulative dose but there is a large variability in its occurrence. The search for additional risk factors for PIPN has thus far yielded no consistent findings. There are currently no neuroprotective strategies to reduce the risk of PIPN, and symptomatic treatment is limited to duloxetine that was found effective in a single phase III intervention study. This review critically examines the pathogenesis, incidence, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of PIPN.

show abstract

Section: Clinical Aspects Of Pipnmentioning

confidence: 99%

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

Staff

Cavaletti

Islam

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

show abstract

“…59 Sjögren's syndrome, 50 vitamin B6 toxicity, 18 cisplatinum toxicity 60 ) Sensory CIDP 61 Abbreviations: CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; HIV, human immunodeficiency virus. 63 heavy metals, organic solvents, acrylamide, 64 cisplatin, 60 vincristine, 65 paclitaxel, 66…”

Section: Leukemiamentioning

confidence: 99%

A Clinician's Approach to Peripheral Neuropathy

Siao

Kaku

2019

Semin Neurol

View full text Add to dashboard Cite

Peripheral neuropathies are a group of disorders that affect the peripheral nervous system, for which hundreds of etiologies have been identified. This article presents a stepwise approach to the evaluation and workup of peripheral neuropathy, which starts with a detailed history of symptoms, family and occupational history, and a neurological as well as general physical exam. Pattern recognition of various neuropathies can help to build a differential diagnosis based on the presentation. Such patterns include acute versus chronic, primary demyelinating versus axonal, hereditary versus acquired, asymmetric versus symmetric, presence of facial palsies, sensory or motor predominant, and presence of prominent autonomic symptoms. Early categorization of the type of neuropathy can help focus the workup for peripheral neuropathy. Nerve conduction studies and electromyography (NCS/EMG) is the primary diagnostic tool in the evaluation of patients with large-fiber polyneuropathy. One of the most important roles of NCS/EMG is to help categorize polyneuropathy as primary axonal versus primary demyelinating. The finding of a primary demyelinating polyneuropathy narrows the differential diagnosis of polyneuropathy dramatically and increases the chances of finding a treatable etiology. Laboratory workup includes serum studies and potentially cerebrospinal fluid, genetic studies, immunological markers, and fat pad biopsy for select patients. Skin biopsy may be used to assess intraepidermal nerve fiber density if small-fiber neuropathy is suspected, and nerve biopsy may be useful in select cases. In recent years, magnetic resonance imaging and neuromuscular ultrasound have also shown promise in the evaluation of peripheral neuropathy. Identification of the etiology of neuropathy is crucial and often time-sensitive, as an increasing number of causes are now reversible or treatable.

show abstract

“…Myositis has been rarely reported in docetaxel‐treated patients with comorbidities, such as diabetes or hypertension . Cardiovagal autonomic dysfunction can be present, with changes in the parasympathetic heart innervation of patients treated with paclitaxel‐based chemotherapy combinations . Cranial nerve involvement is anecdotal .…”

Section: Introductionmentioning

confidence: 99%

Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment

Tamburin

Park

Alberti

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Taxane-induced peripheral neurotoxicity (TIPN) is the most common nonhematological side effect of taxane-based chemotherapy, and may result in dose reductions and discontinuations, having as such a detrimental effect on patients' overall survival. Epothilones share similar mechanism of action with taxanes. The typical TIPN clinical presentation is mainly comprised of numbness and paresthesia, in a stocking-and-glove distribution and may progress more proximally over time, with paclitaxel being more neurotoxic than docetaxel. Motor and autonomic involvement is less common, whereas an acute taxane-induced acute pain syndrome is frequent. Patient reported outcomes questionnaires, clinical evaluation, and instrumental tools offer complementary information in TIPN. Its electrodiagnostic features include reduced/abolished sensory action potentials, and less prominent motor involvement, in keeping with a length-dependent, axonal dying back predominately sensory neuropathy. TIPN is dose-dependent and may be reversible within months after the end of chemotherapy. The single and cumulative delivered dose of taxanes is considered the main risk factor of TIPN development. Apart from the cumulative dose, other risk factors for TIPN include demographic, clinical, and pharmacogenetic features with several single-nucleotide polymorphisms potentially linked with increased susceptibility of TIPN. There are currently no neuroprotective strategies to reduce the risk of TIPN, and symptomatic treatments are very limited. This review critically examines the pathogenesis, incidence, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of TIPN. K E Y W O R D S assessment, chemotherapy, docetaxel, ixabepilone, neurotoxicity, paclitaxel, prevention 1 | INTRODUCTION Taxanes (paclitaxel, docetaxel, cabazitaxel) were among the most important new chemotherapy agents in the late 20th century. 1 Paclitaxel is a natural compound with potent anticancer properties, which was originally isolated from the bark of the Pacific yew tree (Taxus brevifolia) in 1967, but low natural availability and insolubility in water hindered its diffusion since the 1980s. 2 Paclitaxel and docetaxel are currently obtained through a semisynthetic process from a precursor contained in the needles of the European yew tree (Taxus baccata),which is more widely available worldwide. 2 Nanoparticle albuminbound paclitaxel (nab-paclitaxel) is a novel formulation containing human serum albumin to encapsulate hydrophobic paclitaxel molecules to increase tumor uptake and reduce hypersensitivity

show abstract

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

Cited by 23 publications

References 23 publications

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

A Clinician's Approach to Peripheral Neuropathy

Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment

Contact Info

Product

Resources

About